Granta Park-based Nxera Pharma has received a $15million milestone payment after its partner, Neurocrine Biosciences, dosed ...

Medical Devices & Diagnostics Analysts, along with Dr. Jolie Chang, Chief of Sleep Surgery Division at UCSF, discuss 2Q25 sleep medicine trends ...

According to Arizton's latest research report, the Southeast Asia data center market growing at a CAGR of 14.23% during ...

Shares in MaaT Pharma (Euronext: MAAT), a French microbiome company in oncology, closed 25% higher Tuesday. The company ...

Japanese biotech Nxera Pharma (TSE: 4565) has received a $15 million payment from Neurocrine Biosciences (Nasdaq: NBIX) after ...

Cambridge UK and Tokyo biopharma business Nxera Pharma has hauled in $15 million after partner Neurocrine Biosciences dosed the first patient in its Phase 3 registrational programme of NBI-1117568 ...

In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences ...

Nxera Pharma has announced a significant development milestone in its multi-target collaboration with Eli Lilly, marking a ...

Broadcom is set to report its second-quarter results, with Wall Street anticipating a 20% revenue boost, driven by ...

Nxera Pharma just hit a milestone in its collaboration with Eli Lilly, unlocking a confidential payment expected by late 2025. This achievement significantly boosts Nxera’s research efforts in ...

(RTTNews) - Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY) targeting diabetes and ...